
Experts presented results that may transform treatment and clinical practice strategies.
Experts presented results that may transform treatment and clinical practice strategies.
Obesity is associated with increased distant recurrence and breast cancer mortality in all types of early-stage breast cancer.
Emerging research in triple-negative breast cancer highlights the promise of molecular-based approaches to improve treatment outcomes.
AI-powered analysis of mammography images can identify women at high long-term risk of breast cancer, enabling targeted prevention strategies.
Adding anthracyclines to chemotherapy may improve survival in high-risk breast cancer patients.
Advancements in prevention address cancer risk in high-risk patients and BRCA mutation carriers.
Combining CDK4/6 and PDL-1 inhibitors enhances treatment responses in patients with hormone receptor positive and triple-negative breast cancer.
The novel camizestrant-ribociclib combination demonstrated encouraging data in advanced, pre-treated ER+/HER2- breast cancer.
Breast cancer prevention vaccines could have significant positive societal impact by reducing cancer diagnoses.
Novel therapies and personalized treatment plans are improving outcomes for patients with ER-positive breast cancer.
Trastuzumab deruxtecan and trastuzumab emtansine address key challenges such as recurrence and metastases in HER2+ early breast cancer treatment.
The combination of elacestrant and abemaciclib showed promising 8.7-month progression-free survival in ER+, HER2- advanced breast cancer, including in patients with ESR1 mutations.
The assessment of tumor-infiltrating lymphocytes can provide valuable insights to guide personalized treatment decisions for breast cancer patients.
At the 2024 San Antonio Breast Cancer Symposium, experts discussed the development, clinical impact, and challenges of antibody-drug conjugates (ADCs).
Both risk-reducing mastectomy and salpingo-oophorectomy were associated with significant improvements among young BRCA carriers with breast cancer.
Assessing pre-treatment TIL levels in young breast cancer patients could help predict response to neoadjuvant chemotherapy.
Experts highlight the importance of dosing and regimen optimization in breast cancer to improve treatment tolerability, reduce toxicities, and improve quality of life for patients.
Komal Jhaveri MD, FACP, shares that the combination of imlunestrant plus abemaciclib further improved progression-free survival compared to imlunestrant alone.
Virginia Kaklamani, MD, DSc, shares the role of ESR1 mutation testing and combination strategies to optimize endocrine therapy in patients with metastatic HR+/HER2- breast cancer.
Experts discuss advancements in hormone receptor–positive/HER2-negative breast cancer treatment while addressing safety, diversity, and fertility challenges.
pCR rates improve regardless of whether patients received full chemotherapy doses.
Trastuzumab deruxtecan and elacestrant represent important new treatment options.
Pharmacy Times provides a comprehensive recap of the latest advancements in hematology and breast cancer, shared at the 2023 American Society of Hematology and the San Antonio Breast Cancer Symposium conferences
No established standard of care currently exists after spread to the lymph nodes.
The combination resulted in numerically longer OS compared with an NSAI alone.
Significant study results could inform clinical practice strategies.
Douglas Warner, MD, chief medical officer at eFFECTOR, provides a comprehensive overview of zotatifin and its current status in a Phase 1/2 dose escalation and expansion study, with a focus on ER+/HER2- breast cancer.
Heather McArthur, MD, clinical director of breast oncology at UT Southwestern Medical Center, discusses the toxicities associated with antibody-drug conjugates (ADCs) used in breast cancer treatment at the 2023 San Antonio Breast Cancer Symposium.
Troy Bremer, PhD, chief scientific officer at PreludeDx, discusses biosignature model and it's potential in predicting radiation therapy response for those with early-stage invasive breast cancer.